Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: epidermal growth factor receptor C797S inhibitors - Centessa Pharmaceuticals

Next Previous
X
Search
Drug Profile

Research programme: epidermal growth factor receptor C797S inhibitors - Centessa Pharmaceuticals

Alternative Names: C797S inhibitors - Centessa Pharmaceuticals; EGFR C797S inhibitors

Latest Information Update: 05 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PearlRiver Bio
  • Developer Centessa Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 05 Apr 2022 Discontinued - Preclinical for Non-small cell lung cancer in Germany (PO)
  • 15 Nov 2021 PearlRiver Bio announces intention to select candidate in 2022
  • 01 Jul 2021 Preclinical trials in Non-small cell lung cancer in Germany (PO) (Centessa Pharmaceuticals pipeline, July 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top